Tag Archives: Shire

Shire MYDAYIS now available by prescription in the United States

Mydayis, which is now available in the U.S., demonstrated improvements lasting up to 16 hours post-dose, beginning at 2 or 4 hours post-dose, compared to placebo, in total score on a skill-adjusted math test that measures attention in ADHD Lexington, … Read the full press release

Shire submits MAA for lifitegrast: If approved it will address the signs and symptoms of dry eye disease in adults in Europe

Lifitegrast, if approved, would be the first and only new class treatment to address the signs and symptoms of dry eye disease in adults in Europe ZUG, 16-Aug-2017 — /EuropaWire/ — Shire plc (LSE: SHP, NASDAQ: SHPG) announces that the Marketing Authorization … Read the full press release

Shire to present ADHD research at the 170th Annual Meeting of the American Psychiatric Association (APA) in San Diego

Latest Research Supports Greater Understanding of the Evolving Needs of Adults with ADHD Lexington, M.A., 18-May-2017 — /EuropaWire/ — Shire plc (LSE: SHP, NASDAQ: SHPG) will present research on the evolving needs of adults living with Attention-Deficit/Hyperactivity Disorder (ADHD) at the … Read the full press release

Shire unveils powerful spoken word video to raise awareness of some of the issues many adults with ADHD face

Spoken word performer communicates plight of adults with ADHD who remain overlooked and unsupported. ZUG, 25-Oct-2016 — /EuropaWire/ — To mark ADHD Awareness Month, Shire plc (LSE: SHP, NASDAQ: SHPG) has today launched a powerful spoken word video to communicate the … Read the full press release

Shire expands its portfolio of intravenous and subcutaneous immunoglobulin (IG) products with U.S. FDA approval of CUVITRU

Approval follows positive data from clinical studies on efficacy and tolerability, as well as infusion time and number of injection sites Lexington, Mass., 14-Sep-2016 — /EuropaWire/ — Shire plc (LSE: SHP, NASDAQ: SHPG) announced that the United States Food and Drug … Read the full press release

Shire Q2 2016: completed the combination with Baxalta to create the leading global biotechnology company

Integration on track; operating cost synergy expectations increased Pipeline progression continues with FDA approval of XIIDRA for dry eye disease DUBLIN, 04-Aug-2016 — /EuropaWire/ — Shire plc (“Shire”) (LSE: SHP, NASDAQ: SHPG) announces unaudited results for the three months ended June … Read the full press release